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Background: Excessive and inappropriate immune responses are the hallmark of several autoimmune disorders,
including the inflammatory bowel diseases (IBD): Crohn’s disease (CD) and ulcerative colitis (UC). A complex
etiology involving both environmental and genetic factors influences IBD pathogenesis. The role of microRNAs
(miRNAs), noncoding RNAs involved in regulating numerous biological processes, to IBD pathology, in terms of
initiation and progression, remains ill-defined. In the present study, we evaluated the relationship between colon,
peripheral blood, and saliva whole miRNome expression in IBD patients and non-inflammatory bowel disease
(non-IBD) controls to identify miRNAs that could discriminate CD from UC. Quantitative real-time PCR (qRT-PCR)
was used to validate and assess miRNA expression.
Results: Microarray analysis demonstrated that upwards of twenty six miRNAs were changed in CD and UC colon
biopsies relative to the non-IBD controls. CD was associated with the differential expression of 10 miRNAs while UC was
associated with 6 miRNAs in matched colon tissues. CD was associated with altered expression of 6 miRNAs while UC
was associated with 9 miRNAs in whole blood. Expression of miR-101 in CD patients and miR-21, miR-31, miR-142-3p,
and miR-142-5p in UC patients were altered in saliva.
Conclusions: Our results suggest that there is specific miRNA expression patterns associated with UC versus CD
in three separate tissue/body fluids (colon, blood, and saliva). Further, the aberrant miRNA expression profiles
indicate that miRNAs may be contributory to IBD pathogenesis, or at least reflect the underlying inflammation.
Scrutinizing miRNA expression in saliva and blood samples may be beneficial in monitoring or diagnosing
disease in IBD patients. A panel of miRNAs (miR-19a, miR-21, miR-31, miR-101, miR-146a, and miR-375) may be
used as markers to identify and discriminate between CD and UC.
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Crohn’s disease (CD) and ulcerative colitis (UC) are the
two primary and most prevalent forms of inflammatory
bowel disease (IBD). Characterized by inappropriate and
exacerbated immune responses within the gastrointes-
tinal tract, the nature and location of the inflammatory
changes defines each respective disease. Despite years of
research, the exact cause of IBD is still relatively poorly
understood. Nevertheless, it is clear that many factors,
including genetic and epigenetic predispositions, the gut* Correspondence: Jeremy.Schaefer@uth.tmc.edu
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sures, contribute significantly to the disease process.
Linkage analysis and genome wide association studies
(GWAS) have uncovered over 100 loci that have signifi-
cant association with IBD [1-3]. Cytokines (IL-17), cyto-
kine receptors (IL-23 receptor), and bacterial response
elements (CARD15/NOD2, ATG16L1) are just a few of
the pathways that have been found to be either mutated
or otherwise altered in IBD patients and mouse models
of chronic intestinal inflammation [2-5].
MicroRNAs (miRNAs), single stranded RNA mole-
cules of 19–25 nucleotides, are poised to make signifi-
cant contributions to defining the multifactorial etiology
and pathobiology of IBD. Initially discovered in the early
1990s, this novel class of noncoding RNAs regulatesl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion and/or promote mRNA degradation [6-9]. The
biological footprint of miRNAs is widespread; over
30% of the genome is predicted to be actively regulated
by miRNAs and studies have shown that miRNAs are
involved in the control of a variety of normal cellular
events including differentiation, organogenesis, and
metabolism [10,11]. Further, aberrant expression of
miRNAs has been associated with a growing number
of disease states, including cancer and autoimmune
diseases [12-17].
However, the consequence of how the alterations in
miRNA expression occur and contribute to disease
pathobiology remains mostly intangible at the moment.
Understanding the role of miRNAs in the regulation of
inflammation is an area of importance that may have
broad significance to understanding the pathogenesis
of IBD as well as a number of other diseases. Several
studies have identified miRNAs that are associated
with IBD in intestinal tissues and peripheral blood
specimens [18-24]. In a previous study involving the
interleukin-10 knockout (IL-10−/−) mice, a mouse
model of chronic intestinal inflammation, we demon-
strated selective dysregulation of miRNAs in colon tis-
sue and peripheral blood leukocytes [25]. We therefore
postulated that miRNA expression would be similarly
disrupted in IBD patients with the possibility that
some of the same miRNAs might have altered expres-
sion. The purpose of this study was to identify differ-
entially expressed miRNAs that could selectively
discriminate CD from UC and healthy controls using
colon, blood, and saliva specimens. A further goal was
to determine how the tissue microenvironment affected
miRNA expression.
Results
Whole miRNome expression analysis in human IBD colon
biopsies
To systematically analyze miRNA expression in IBD
patients and identify candidate miRNAs for subsequent
validation, expression analysis using oligonucleotide
microarrays was initially performed on a small number
of colon tissue biopsies from CD, UC, and non-IBD
(Normal, NL) patients. Among the over 600 miRNA
probes, the microarray detected 89 miRNAs with fold
changes > 0.5 (Figure 1A) and 26 miRNAs with fold
changes > 3.0 over the mean (Figure 1B).
miRNAs are differentially expressed in CD and UC
intestinal biopsies
From the initial microarray screen, we selected 12 miR-
NAs for further validation. Among the qualities that fac-
tored into the inclusion of select miRNAs for validation
was overall expression pattern, magnitude of expression,and previous associations with inflammation or disease.
In terms of overall expression, we looked to include
miRNAs that had consistent elevated or reduced expres-
sion in either the two CD or two UC biopsies relative to
the non-IBD biopsy. miR-21, miR-26a, miR-101, miR-
142-3p, miR-142-5p, miR-146a, miR-155, miR-223, and
miR-494 were identified as candidate miRNAs in this
manner. As an example miR-142-5p expression was
decreased in both UC biopsies relative to the non-IBD
biopsy. miR-26, miR-142-3p, and miR-223 were chosen
as they were among the few miRNAs that had fold
changes > 3.0 over the mean (Figure 1B). miR-19a, miR-31,
and miR-375 were included as these miRNAs were
elevated in our previous study with IL-10−/− mice or
are associated with disease [25].
To validate miRNA expression, three separate
condition-specific groups (NL, CD, or UC ) were each
made by pooling total RNA from the corresponding NL,
CD, or UC patient groups (n ≥ 20 biopsies per group)
and analyzed via qRT-PCR for the selected miRNAs. In
these pooled colon biopsies miR-31, miR-101, and miR-
146a were significantly elevated in the CD samples while
miR-375 was significantly reduced relative to the NL
samples (Figure 2, column 1 & 4; p < 0.05). miR-19a,
miR-21, miR-31, and miR-101 levels were significantly
elevated in UC colon biopsies relative to the NL samples
(Figure 2, column 1 & 4; p < 0.05). Secondary analysis
using a Bonferroni correction (α = 0.05; n = 12) revealed
that miR-146a was statistically elevated in CD biopsies
(p < 0.004).Circulating miRNAs are differentially expressed in CD and
UC blood
To advance our knowledge in using less-invasive
methods to screen for IBD, we characterized the extra-
intestinal expression of miRNAs in peripheral blood.
Peripheral blood is frequently used as a diagnostic tool
for a varied number of diseases and conditions from
simple cholesterol screenings to advanced genetic
screens. Currently, there is not a single blood test that
can make a diagnosis of IBD on its own merits; rather,
multiple tests are required to come to a diagnosis of
IBD. Thus, we explored the possibility of using whole
blood miRNA expression profiling as an IBD diagnostic
tool.
In order to determine if the miRNA profile uncovered
in the colon biopsies could be replicated in a circulating
extra-intestinal body fluid, whole blood was collected to
examine miRNA expression levels. As above, total RNA
from the blood specimens were pooled into three separ-
ate condition-specific groups (NL, CD, or UC) and ana-
lyzed for miRNA expression via qRT-PCR. A total of ten
miRNAs (6 with CD and 9 with UC) had statistically
Figure 1 Heat map and unsupervised hierarchical clustering of miRNAs in IBD colon biopsies indicate dysregulation of miRNA expression. The
miRCURY LNA microarray microRNA profiling service was used to examine miRNA expression in colon biopsies from Normal, CD, and UC subjects. (A)
Heat map of fold changes > 0.5. (B) Heat map of fold changes > 3.0. Red color represents an expression level above mean, blue color represents
expression lower than the mean. A Delta Log Median ratio of +/−1.0 is equal to a fold change of +/− 2.0.
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Figure 2 miRNA expression is altered in colon, blood, and saliva from Crohn’s disease and ulcerative colitis subjects. Total RNA from NL,
CD, and UC colon biopsies was pooled and used for TaqMan qRT-PCR analysis for the indicated miRNAs. miRNA expression was normalized to U6
expression. Statistical significance was calculated using the Student’s t-test relative to the healthy NL control. At least 23 distinct specimens were
included in each pooled group of colon biopsies. 30 and 5 distinct specimens were included in each pooled group of blood and saliva
samples, respectively.
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pools versus non-IBD blood pools. In CD blood samples,
miR-21, miR-31, miR-146a, and miR-155 were signifi-
cantly reduced while miR-101 and miR-375 were signifi-
cantly elevated relative to the NL samples (Figure 2,
column 2 & 5; p < 0.05). miR-21, miR-31, and miR-146a
were statistically significantly reduced and miR-19a,
miR-101, miR142-5p, miR-223, miR-375, and miR-494
were statistically significantly elevated in UC blood sam-
ples relative to the NL samples (Figure 2, column 2 & 5;
p < 0.05). Of these, miR-19a, miR-31, miR-101, miR-142-
5p, miR-146a, miR-155, miR-223, miR-375, and miR-494
had not previously been associated with IBD to our
knowledge. However, miR-21 has previously been shown
to be differentially expressed in IBD [26,27]. In our pre-
vious study with IL-10−/− mice, miR-19a, miR-31, miR-101, miR-142-5p, miR-146a, miR-155, miR-223, and
miR-375 were selectively dysregulated in whole blood of
mice with mild intestinal pathology [25]. Secondary ana-
lysis using a Bonferroni correction (α = 0.05; n = 12) re-
vealed that miR-21, miR-31, miR-142-5p, and miR-146a
expression was significantly altered in CD and UC blood
specimens (p < 0.004).
Evaluation of miRNA expression in oral fluid
Saliva is an important body fluid containing enzymatic
proteins to begin digestion and antimicrobial proteins
for immune protection. Similar to the peripheral blood,
during pathophysiological states, such as cancer and
inflammation, the composition of saliva can become
altered as a reflection of these conditions [28,29]. More-
over, saliva provides a more accurate ‘real-time read-out’
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patients. In addition, evidence suggests that saliva con-
tains a transcriptome of thousands of mRNAs including
miRNA [30-34]. Furthermore, due to the non-invasive
nature of saliva collection for analytical purposes, saliva
collection does not compromise a patient’s skin barrier
nor does it require sedation, saliva is the ideal fluid for
procuring multiple isolates to monitor disease progres-
sion. In our study, 5 miRNAs (1 CD and 4 UC) had sta-
tistically significant altered expression in pooled saliva
samples from IBD patients relative to the non-IBD con-
trols. In pooled saliva samples, miR-101 was significantly
elevated in CD relative to the NL samples while miR-21,
miR-31, and miR-142-3p were significantly elevated in
UC relative to the NL samples (Figure 2, column 3; p <
0.05). miR-142-5p expression was significantly lowered
in UC saliva samples relative to the NL samples (Figure 2,
column 6; p < 0.05). No saliva specimens were statisti-
cally significant following a secondary analysis using a
Bonferroni correction (α = 0.05; n = 12; p < 0.004).
To our knowledge this represents the first report of
salivary miRNA diagnostics in IBD patients. Thus,
examining the expression of miR-101, miR-21, miR-31,
miR-142-3p, and miR-142-5p in saliva may be able to
assist in diagnosing IBD.
The pooled colon, pooled blood, and pooled saliva
specimen results are summarized in Additional file 1:
Table S1 and Table S2 for CD and UC, respectively.
miRNA expression profiles were altered in the extra-
intestinal body fluids suggesting that these sources may
effectively reflect the intestinal inflammation in IBD.
miR-101, in particular, may be a key miRNA regulator in
IBD, as it was statistically elevated in all three tissues
from CD patients and two of the three UC tissues rela-
tive to the NL tissues.
miRNA expression is differentially expressed in matched
colon biopsies from CD and UC subjects
As CD in particular is characterized by patchy areas of
involved, inflamed tissues, we next sought to determine
if a spatial relationship exists in miRNA expression pat-
terns between these pockets of intestinal pathology and
non-involved tissue in CD and UC. Paired endoscopic-
ally uninvolved (EU) and endoscopically involved (EI)
colon biopsies from the same CD (Figure 3) or UC pa-
tients (Figure 4) were drawn from the previously ana-
lyzed pooled groups to examine their miRNA profiles. In
the CD paired colon biopsies, nine miRNAs (miR-21,
miR-31, miR-101, miR-142-3p, miR-142-5p, miR-155,
miR-223, miR-375, and miR-494) were elevated at a sta-
tistically significant level in the endoscopically involved
colonic tissue in comparison to the endoscopically unin-
volved colonic tissue (Figure 3, Table 1). miR-21, miR-
101, miR-142-5p, miR-146a, miR-155, and miR-223 wereelevated at a statistically significant level in the UC
endoscopically involved colonic tissue in comparison to
the endoscopically uninvolved colonic tissue (Figure 4,
Table 1). Although miR-31 was the most highly expressed
miRNA in both the CD and UC matched pairs, it was
statistically significant in only the CD pairs.
In the miRNA microarray analysis, several of the
non-annotated, human miRPlus miRNA candidates had
altered expression (Figure 1A-B). miRPlus miRNA can-
didates are predicted miRNA sequences derived from
Exiqon’s database of proprietary material, database
mining, and publications. We investigated the expres-
sion of the top seven of these miRPlus miRNAs that
were altered in the microarray analysis. In the matched
CD biopsies, miRPlus-E1067 and miRPlus-E1117 were
statistically significantly reduced while miRPlus-E1028
and miRPlus-F1202 were statistically significantly ele-
vated in the endoscopically involved colonic tissue in
comparison to the endoscopically uninvolved colonic
tissue (Additional file 2: Figure S1). In the matched UC
biopsies, miRPlus-E1067, miRPlus-E1088, and miRPlus-
E1117 were statistically significantly reduced in the endo-
scopically involved colonic tissue in comparison to the
endoscopically uninvolved colonic tissue (Additional file 3:
Figure S2).
To confirm the reproducibility of the qRT-PCR ana-
lysis, biopsies were run in replicate; results for individ-
ual runs for 9 of the 12 miRNAs analyzed are shown
(Additional file 4: Figure S3A). This confirms that there
is little intra-sample variation between qRT-PCR runs.
We next decided to examine the expression of three
miRNAs (miR-31, miR-146a, and miR-375) in pooled
endoscopically uninvolved versus endoscopically in-
volved IBD patient biopsies to determine if this panel of
miRNAs could be used to separate CD from UC. A gen-
eral pattern (Table 1) emerged for these 3 miRNAs in
the paired analysis; miR-31 and miR-375 expression was
increased at a statistically significant level in CD but not
UC, while miR-146a is increased at a statistically signifi-
cant level in UC but not CD. The CD and UC pairs from
Figures 3 and 4 were pooled into endoscopically unin-
volved versus endoscopically involved groups of CD or
UC, respectively (CD EI, CD EU, UC EU, UC EI). Ele-
vated expression of miR-31, miR-146a, and miR-375 was
present in the CD pool while miR-31 and miR-146a were
elevated in UC (Additional file 4: Figure S3B).
Roquin-1 and ATG16L1 expression is reduced in matched
colon biopsies from CD but not UC subjects
To better understand the relationship that exists be-
tween miRNA expression and potential gene targets of
interest, we used web-based target prediction programs
(miRDB and TargetScan) to identify potential miRNA
target genes (Additional file 1: Table S3). Of the
Figure 3 (See legend on next page.)
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Figure 3 miRNA expression is differentially expressed in matched colon biopsies from Crohn’s disease subjects. Total RNA was isolated
from matched endoscopically uninvolved (EU) and endoscopically involved (EI) colon biopsies from CD subjects. The RNA samples were used for
TaqMan qRT-PCR analysis for the indicated miRNAs. miRNA expression was normalized to U6 expression. Pairings were subdivided according to
miRNA expression trends. Statistical significance was calculated using the Student’s paired t-test relative to the endoscopically uninvolved
CD tissue.
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(RC3H1), a RING finger E3 ligase with immunoregula-
tory properties in mice, was a common target for seven
of the miRNAs with elevated expression. Autophagy
related 16-like 1 (ATG16L1), one of the most commonly
detected genetic variations in CD patients, was predicted
to be a target of miR-142-3p [35,36]. Our unpublished
observations and others have experimentally confirmed
ATG16L1 as a regulatory target of miR-142-3p and
miR-93-5p [37,38].
Analysis of Roquin-1 mRNA expression in the paired
endoscopically uninvolved (EU) versus the endoscopically
involved (EI) CD colon biopsies revealed statistically sig-
nificant decreased expression of Roquin-1 in a subset of
CD patients (Figure 5A). There was no appreciable
difference in UC (Figure 5B). ATG16L1 expression
was statistically decreased in a subset of CD patients
(Figure 5C). Conversely, ATG16L1 expression was sta-
tistically increased in a subset of UC (Figure 5D).
Discussion
In the present study into the miRNA regulatory network
of IBD, we were able to identify miRNAs (miR-19a, miR-
21, miR-31, miR-101, miR-146a, and miR-375) that had
statistically significant altered expression in pooled colon
biopsy samples with several other miRNAs just outside
the significance threshold (miR-26a, miR-142-3p, miR-
155, miR-223, and miR-494; p ≤ 0.1). Of these miRNAs,
miR-21, miR-31, miR-146a, and miR-375 have been
identified in previous studies examining miRNA expres-
sion in CD and UC colon biopsies [18-21]. Further, these
miRNAs are implicated in inflammation and cancer with
miR-21 and miR-375 functioning as oncomiRs while
miR-146a has been reported to be a tumor suppressor
[39-41]. miR-31 is more complicated in that it has been
reported to be both an oncomiR in lung cancer, and a
tumor suppressor in breast cancer [42,43]. The increased
expression of miR-146a and possibly miR-31 seem to be
attempts to rein in the chronic inflammatory response
in IBD. Previous studies that established miR-146a func-
tionally opposing the effects of miR-155 via regulation of
inflammatory signaling proteins, particularly NF-κB,
support this [44-47]. miR-155 overexpression in mice
results in a myeloproliferative disorder [44]. Conversely,
miR-146a knockout mice develop hyperinflammatory
and immunoproliferative disorders [45-47]. This sug-
gests that, in IBD, the balance between these miRNAswith seemingly opposing functions is tilted and begs the
question as to why the pro-inflammatory miRNAs win.
We additionally identified two miRNAs, miR-19a and
miR-101, that have not previously been associated with
IBD. miR-19a is a member of the miR-17-92 cluster and
has been shown to be overexpressed in T-cell acute
lymphoblastic leukemia and multiple myeloma where it
was revealed that miR-19a negatively regulates the ex-
pression of CYLD and SOCS-1 respectively to promote
cell survival and pathogenesis [48,49]. miR-101 has been
associated with inflammation as a negative regulator of
inducible costimulator (ICOS) and cancer cell stemness
as a negative regulator of the corepressor C-terminal
binding protein-2 (CtBP2) [50,51]. Once again, two miR-
NAs with seemingly opposing targets, miR-19a is pro-
inflammatory while miR-101 is anti-proliferative, are
both elevated in IBD.
Further, we were able to demonstrate that CD was
associated with the differential expression of 10 miRNAs
in a statistically significant manner (9 elevated, 1 de-
creased) while 6 miRNAs were elevated in a statistically
significant manner in UC when comparing matched
endoscopically uninvolved colon biopsies with endo-
scopically involved colon biopsies. Of these miRNAs,
miR-21, miR-101, miR-142-5p, miR-155, and miR-223
had overlapping expression patterns between CD and
UC. miR-146a was elevated in a statistically significant
manner only in UC in the paired analysis while miR-19a,
miR-31, miR-142-3p, miR-375, and miR-494 were
altered in a statistically significant manner in CD.
Taken together, our analysis of the pooled colon sam-
ples versus the matched colon biopsies provides crucial
but distinct information regarding the role of miRNAs
in IBD. The former analysis suggests that a panel of
miRNAs (miR-19a, miR-21, miR-31, miR-101, miR-146a,
and miR-375) may be used as markers to identify and
discriminate between CD and UC. The latter analysis
provides more mechanistic information regarding miRNA
involvement in disease pathology. Namely, it points to the
underlying pathways that the miRNAs are altering to
cause or promote disease. As an example, the overexpres-
sion of miR-31 and miR-146a, both of which target
CD40L (predicted or experimentally confirmed), in the
matched samples suggests that the CD40:CD40L costi-
mulatory pathway plays an important role in promoting
localized inflammation; CD40 and CD40L are elevated
in IBD [52]. With further studies, we may even be able
Figure 4 (See legend on next page.)
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Figure 4 miRNA expression is differentially expressed in matched colon biopsies from ulcerative colitis subjects. Total RNA was isolated
from matched endoscopically uninvolved (EU) and endoscopically involved (EI) colon biopsies from UC subjects. The RNA samples were used for
TaqMan qRT-PCR analysis for the indicated miRNAs. miRNA expression was normalized to U6 expression. Pairings were subdivided according to
miRNA expression trends. Statistical significance was calculated using the Student’s paired t-test relative to the endoscopically uninvolved
UC tissue.
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based on miRNA analysis.
As a proof of concept, we analyzed miRNA expression
in the saliva of IBD patients. This new frontier of RNA
diagnostics in oral fluids is being pioneered in the detec-
tion of cancer [33,53-56]. Although salivary miRNAs are
emerging as a novel class of biomarkers in cancer, they
have yet to be examined in other non-cancer diseases. In
our study, we were able to detect differences in miRNA
expression in the oral fluid from IBD patients. miR-21 in
particular is a ubiquitous miRNA associated with many
diseases and is an oncomiR [57,58]. Likewise, miR-31
and miR-101 have been implicated in cancer as well with
the former being described as an oncomiR while the lat-
ter behaves as a tumor suppressor [43,59,60]. Finally,
our results identified a potentially new IBD associated
gene. In a subset of CD patients, RC3H1 expression was
reduced in statistically significant manner in a subset of
the endoscopically involved versus endoscopically unin-
volved matched colony biopsy pairs. In mouse models
deficient for Rc3h1, either the sanroque missense muta-
tion (Rc3h1san/san) mouse or a genetrap knockout
(Rc3h1gt/gt) mouse, an acute small intestinal inflamma-
tion develops among other phenotypes [50,61,62].
Roquin-1 is involved in the post-transcriptional regulation
of mRNA. Roquin-1 localizes to P bodies and stress gran-
ules and plays a role in regulating mRNA turnover, andTable 1 Summary of microRNA changes in paired colon biops
Crohn’s disease
miRNA N (Pairs) Reduced (p-value) Elevated (p-va
miR-19a 10 6 (0.050)* 4 (0.307)
miR-21 10 4 (0.082) 6 (0.024)*
miR-26a 10 7 (0.064) 3 (0.186)
miR-31 10 1 (ND) 9 (0.002)*
miR-101 10 5 (0.043) 5 (0.041)*
miR-142-3p 10 2 (0.096) 8 (0.018)*
miR-142-5p 10 2 (0.133) 8 (0.032)*
miR-146a 10 4 ( 0.121) 6 (0.148)
miR-155 10 4 (0.073) 6 (0.024)*
miR-223 10 1 (ND) 9 (0.006)*
miR-375 10 2 (0.353) 8 (0.023)*
miR-494 10 5 (0.136) 5 (0.048)*
ND, not determined due to insufficient number of samples in group.
*statistically significant values, p < 0.05.has been shown to regulate the expression of T cell coacti-
vators, specifically ICOS and OX40 as well as the cyto-
kines TNFα and IL-17. Given this role and the number of
altered IBD-related miRNAs predicted or confirmed to
target Roquin-1 (Additional file 1: Table S3), the im-
portance of Roquin-1 in intestinal inflammation and
human IBD necessitates further study.
This study also affirms the use of the IL-10−/−
mouse as an effective model of IBD as miRNAs identi-
fied as differentially expressed in the CD and UC hu-
man samples were shared with the IL-10−/− mice [25].
Although there are frequently difficulties in going from
bench to bedside, at least in this instance it seems that
the IL-10−/− mouse model faithfully recreates some
aspects of IBD.
Conclusions
In summary, selective sets of miRNA expression profiles
may serve to separate CD and UC diagnostically. In this
study, differentially expressed miRNAs in endoscopically
involved versus endoscopically uninvolved CD and UC
colon biopsies were discovered that indicate that a distinct
miRNA profile exists within the intestinal microenviron-
ment of IBD patients. Further, these study results provide
support for the feasibility of using saliva and blood as diag-
nostic tools and advances the search for viable early detec-
tion methods for IBD. Importantly, this is the first report ofies from Crohn’s disease and ulcerative colitis subjects
Ulcerative colitis
lue) N (Pairs) Reduced (p-value) Elevated (p-value)
7 3 (0.136) 4 (0.059)
7 2 (0.203) 5 (0.029)*
7 3 (0.072) 4 (0.131)
7 0 (ND) 7 (0.177)
7 1 (ND) 6 (0.023)*
7 1 (ND) 6 (0.053)
7 0 (ND) 7 (0.017)*
7 0 (ND) 7 (0.015)*
7 0 (ND) 7 (0.016)*
7 0 (ND) 7 (0.006)*
7 3 (0.174) 4 (0.060)
7 2 (0.094) 5 (0.134)
Figure 5 Roquin-1 and ATG16L1 expression is differentially expressed in a subset of CD and UC subjects. Total RNA from matched
endoscopically uninvolved (EU) and endoscopically involved (EI) colon biopsies from (A, C) CD and (B, D) UC subjects was used to analyze
Roquin-1 or ATG16L1 expression via qRT-PCR. Gene expression was normalized to GAPDH. Pairings were subdivided according to Roquin-1
or ATG16L1 expression trends. Statistical significance was calculated using the Student’s paired t-test relative to the endoscopically uninvolved IBD tissue.




Fresh-frozen colonic mucosa was sampled via endo-
scopic pinch biopsies from the following groups: 1) CD,
2) UC, and 3) normal, healthy individuals scheduled for
clinically indicated colonoscopies unrelated to IBD. For
the CD and UC patients, one or two pinch biopsies were
taken from endoscopically uninvolved appearing mucosa
(EU) and a similar number from endoscopically involved
(EI) tissue near the other site when possible. The pinch
biopsies were immediately placed in RNALater for sub-
sequent RNA isolation and analysis of miRNAexpression. Blood and saliva samples were collected
from the same groupings above albeit not the same indi-
viduals as from which the pinch biopsies were collected.
Whole blood was collected in PAXgene Blood RNA
Tubes (PreAnalytiX, Switzerland) while unstimulated
saliva was collected in vessels containing the RNApro-
tect Saliva reagent (Qiagen, Valencia, CA). In total, 195
patient samples have been assessed from 35 controls,
42 CD, and 41 UC patients and broken down as: 23
UC pinch biopsies (7 matched pairs), 33 CD pinch bi-
opsies (10 matched pairs), 34 normal pinch biopsies; 30
blood samples per group; and 5 saliva samples per
group. All patient samples were collected under the
auspices of protocols approved by The University of
Texas Health Science Center at Houston Committee
Schaefer et al. BMC Immunology  (2015) 16:5 Page 11 of 13for the Protection of Human Subjects (the Institutional
Review Board at UTHealth) and the Institutional Review
Board for Baylor College of Medicine and Affiliated
Hospitals. Written informed consent and informed
assent (to level of age-related understanding) was
obtained after the attending physician introduced the
opportunity for study participation to the participants,
or where appropriate, to the legal representative/parent
(s) of the participants. Patient characteristics are de-
tailed in Table 2.
Isolation of RNA and real-time quantitative PCR (qRT-PCR)
Total RNA was isolated from colon biopsies using the miR-
Neasy Minikit (Qiagen) according to the manufacturer’s
instructions. The RNeasy Protect Saliva Minikit (Qiagen)
was used to isolate total RNA from the saliva samples with
a minor modification recommended by the manufacturer.
The PAXgene Blood miRNA Kit (PreAnalytiX) was used to
isolate total RNA from the blood samples. cDNA was
synthesized using either the High-Capacity cDNA Reverse
Transcription Kit or the Taqman microRNA Reverse
Transcription Kit (Applied Biosystems, Grand Island,
NY). miRNA expression was quantified using TaqMan
microRNA assays with the TaqMan Universal Master
Mix II, No UNG reagent. To measure Roquin-1 and
GAPDH transcript levels, either the Power SYBR Green
PCR Master Mix (Applied Biosystems) or the TaqMan
Universal Master Mix II, No UNG (Applied Biosystems)
was used according to the manufacturer’s instructions.
Samples were analyzed using the StepOnePlus real-time
thermal cycler (Applied Biosystems) and software. Relative
gene expression was calculated using the 2-ΔΔCt methodTable 2 Characteristics of IBD patients and controls
CD UC Controls
No. of patients (total) 42 41 35
Patient specimens
Pinch biopsies 33 23 34
Blood 30 30 30
Saliva 5 5 5
Sex
Male, n (%) 20 (47.6) 28 (68.3) 13 (37.1)
Female, n (%) 22 (52.4) 13 (31.7) 22 (62.9)
Age (y)
Mean 42.7 47.6 56.6
Male 46.7 50.3 55.4
Female 39 41.8 57.4
Range 18-71 18-88 26-82
Male 18-71 27-88 26-82
Female 19-65 18-62 34-75and normalized to either GAPDH or U6 snRNA [63].
Roquin-1 and GAPDH gene specific primers were de-
signed and purchased from Integrated DNA Technologies
(Coralville, IA): Roquin-1 Forward, 5′-ACCAACCTTGC
CTCCTACCT-3′, Roquin-1 Reverse, 5′-TAATCGCTGG
TCCCTCATTC -3′; GAPDH Forward, 5′-TGCACCACC
AACTGCTTAGC-3′, GAPDH Reverse, 5′-GGCATGGA
CTGTGGTCATGAG-3′. Taqman assays for mature miR-
NAs were purchased from Applied Biosystems.
miRNA Microarray
Total RNA (~1,000 ng each) from 1 healthy normal, 2
CD, and 2 UC colon biopsies were submitted to Exiqon
(Woburn, MA) for miRNA expression analysis via the
miRCURY LNA microarray microRNA profiling service.
The miRNA array data has been deposited in the NCBI
Gene Expression Omnibus (GEO) under the entry series
GSE53867.
Statistical analysis
The statistical significance of data from these studies was
determined using either an unpaired, two-sided Student’s t
test (pooled samples) or a paired, two-sided Student’s t test
(matched samples) in Excel. Data are presented as mean +
SEM. Differences were considered statistically significant
if p ≤ 0.05. A secondary analysis using the Bonferroni cor-
rection was included; differences were considered statisti-
cally significant if p ≤ 0.004.Additional files
Additional file 1: Table S1. MicroRNAs with statistically significant
altered expression in Crohn’s disease by tissue site from pooled samples.
Table S2. MicroRNAs with statistically significant altered expression in
ulcerative colitis by tissue site from pooled samples. Table S3. Potential
Targets for miRNAs with Elevated Expression in IBD.
Additional file 2: Figure S1. miRPlus miRNA expression is altered in
matched colon biopsies from Crohn’s disease subjects. Total RNA was
isolated from matched endoscopically uninvolved (EU) and
endoscopically involved (EI) colon biopsies from CD subjects. The RNA
samples were used for SYBR Green qRT-PCR analysis for the indicated
miRNAs. miRNA expression was normalized to U6 expression. Pairings
were subdivided according to miRNA expression trends. Statistical significance
was calculated using the Student’s paired t-test relative to the endoscopically
uninvolved CD tissue.
Additional file 3: Figure S2. miRPlus miRNA expression is altered in
matched colon biopsies from ulcerative colitis subjects. Total RNA was
isolated from matched endoscopically uninvolved (EU) and endoscopically
involved (EI) colon biopsies from UC subjects. The RNA samples were used
for SYBR Green qRT-PCR analysis for the indicated miRNAs. miRNA expression
was normalized to U6 expression. Pairings were subdivided according to
miRNA expression trends. Statistical significance was calculated using the
Student’s paired t-test relative to the endoscopically uninvolved UC tissue.
Additional file 4: Figure S3. Specificity and reproducibility of miRNA
expression colon biopsies. (A) Replicate runs of RNA samples from matched
endoscopically uninvolved versus endoscopically involved CD patient biopsies.
Samples were analyzed via TaqMan qRT-PCR for the indicated miRNAs. (B)
qRT-PCR analysis of miR-31, miR-146a, and miR-375 in pooled endoscopically
uninvolved versus endoscopically involved CD and UC patient biopsies.
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